FIELD: medicine, oncology, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition that shows the improved antitumor effect and reduced adverse effect(s). The composition comprises an active substance eliciting an antitumor effect or its pharmaceutically acceptable salt and derivative of hydroxamic acid by formula or therapeutically useful its acid additive salt. EFFECT: enhanced antitumor activity of composition. 10 cl, 10 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION ELICITING IMPROVED ANTITUMOR EFFECT AND/OR REDUCED ADVERSE EFFECTS AND COMPRISING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2254129C2 |
| ANTITUMOR THERAPEUTIC PREPARATIONS INCLUDING THE COMBINATION OF CARTILAGINOUS EXTRACT AND THAT OF ANTINEOPLASTIC AGENT PROVIDING HIGH EFFICIENCY AT LOW TOXIC SIDE EFFECTS | 1998 |
|
RU2195946C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| METHOD FOR ENHANCING EFFECTIVENESS OF ANTITUMOR AGENTS | 2000 |
|
RU2271829C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING DERIVATIVES OF HYDROXAMIC ACID | 1996 |
|
RU2191005C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| METHOD AND COMPOSITION FOR CANCER DISEASE TREATMENT, TOSYLATE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-N'-(4-(2-(N-METHYLCARBAMOYL)-4-PYRIDYLOXY)PHENYL)UREA | 2002 |
|
RU2316326C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
